abs439.txt	like	ras	proteins		the	aberrant	function	of	rho	family	small	gtpases	has	beenimplicated	in	driving	cancer	development	and	growth		however		unlike	the	rasfamily		where	gain-of-function	missense	mutations	are	found	in	âˆ¼25%	of	all	humancancers		missense	mutations	are	relatively	rare	in	rho	proteins		instead		alteredrho	activity	in	cancer	more	commonly	arises	through	the	aberrant	functions	of	rhogtpase	regulators		in	many	cancer	types		altered	expression	and/or	mutation	ofrho-selective	guanine	nucleotide	exchange	factors	(rhogefs)	or	gtpase-activatingproteins	(rhogaps)		which	activate	or	inactivate	rho	gtpases		respectively		isobserved		for	example		deletion	or	loss	of	expression	of	the	rhoa	gap	dlc1	iswell-established	to	drive	cancer	growth		recently		we	identified	high	expressionof	2	rhogaps		arhgap11a	and	racgap1		in	the	basal-like	breast	cancer	subtype	unexpectedly		both	of	these	rhoa	gaps	exhibited	properties	of	oncoproteins	ratherthan	tumor	suppressors		in	contrast	to	dlc1		in	this	commentary		we	summarize	ourfindings	and	speculate	that	different	rhoa	gaps	can	play	distinct	roles	in	cancerdepending	on	their	spatial	regulation	and	cancer	type	context		we	also	evaluateour	results	in	light	of	recently-described	cancer	genome	sequencing	studies	thathave	identified	loss-of-function	mutations	of	rhoa	in	specific	cancer	types	
